Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Industry Communications With Payors: US FDA Okays Info On Investigational Drugs

January 19, 2017, The Pink Sheet

Michael Labson is quoted by The Pink Sheet in an article regarding FDA’s draft guidance on payor communications. According to Labson, the draft guidance is consistent with changes from the 21st Century Cures Act and evolving case law on the First Amendment, and "provides additional important flexibility for manufacturers to communicate science-based information to payors." He adds that the guidance "seems to articulate a relatively broad science-based standard," noting that it appears to recognize that health care economic information could include treatment comparisons in the absence of head-to-head comparisons.

Share this article: